XTL Biopharmaceuticals Ltd. (XTLB)
| Market Cap | 7.10M -53.0% |
| Revenue (ttm) | n/a |
| Net Income | -6.97M |
| EPS | -0.01 |
| Shares Out | 982.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,090 |
| Open | 1.926 |
| Previous Close | 1.920 |
| Day's Range | 1.880 - 1.950 |
| 52-Week Range | 1.920 - 6.240 |
| Beta | 0.43 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 30, 2026 |
About XTLB
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company’s lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies... [Read more]
Financial Performance
Financial StatementsNews
XTL BioPharma Closes Acquisition Of Psyga Bio; Shifts Focus To Psychedelic Therapies
(RTTNews) - XTL Biopharmaceuticals Ltd. (XTLB) announced the completion of the acquisition of Psyga Bio Ltd. With the transaction's closure, psychedelic operations will become XTL's exclusive core bus...
XTL Completed the Acquisition of Psyga Bio Ltd.
expands its IP portfolio to clinical-stage biopharmaceutical assets XTL Biopharmaceuticals (XTL) Completes the Acquisition of Psyga Bio and Establishes Psychedelic Biotechnology Platform At a historic...
XTL Biopharmaceuticals (XTLB) Faces Nasdaq Compliance Challenges Amid Stock Surge
XTL Biopharmaceuticals (XTLB) Faces Nasdaq Compliance Challenges Amid Stock Surge
XTL Announces Receipt of Staff Delist Determination from Nasdaq
RAMAT GAN, ISRAEL, May 22, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from...
3 Penny Stocks to Watch Now, 4/30/26
XTL Biopharmaceuticals ($XTLB), Rising Dragon Acquisition Corp. ($RDAC), and Akanda Corp. ($AKAN) are the three penny stocks to watch on April 30, according to TipRanks’ Penny Stock Screener tool. Pen...
XTL Biopharmaceuticals (XTLB) to Acquire Psyga Bio, Shares Surge 58.7%
XTL Biopharmaceuticals (XTLB) to Acquire Psyga Bio, Shares Surge 58.7%
XTL Biopharmaceuticals to acquire Psyga Bio
XTL Biopharmaceuticals (XTLB) announced that it has entered into a definitive share purchase agreement to acquire 100% of the issued and outstanding share capital of Psyga Bio. Psyga operates a
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum
XTL Biopharmaceuticals trading halted, news pending
19:50 EDT XTL Biopharmaceuticals (XTLB) trading halted, news pending
XTL Biopharmaceuticals (XTLB) Adjusts ADS to Ordinary Share Ratio
XTL Biopharmaceuticals (XTLB) Adjusts ADS to Ordinary Share Ratio
XTL Biopharmaceuticals announces ADS ratio change
XTL Biopharmaceuticals (XTLB) announced that it plans to change the ratio of its American depositary shares to its ordinary shares, par value NIS 0.1 per share, from the current ADS
XTL Biopharmaceuticals Announces ADS Ratio Change
RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it plans to change the ratio of its Americ...
Beyond Air announces termination of NeuroNOS agreement with XTL
Beyond Air (XAIR) announced that the previously disclosed proposed transaction with XTL Biopharmaceuticals (XTLB) relating to Beyond Air’s NeuroNOS subsidiary has been terminated. The companies entere...
XTL Biopharmaceuticals (XTLB) Faces Nasdaq Delisting Threat
XTL Biopharmaceuticals (XTLB) Faces Nasdaq Delisting Threat
XTL Biopharmaceuticals gets delisting letter from Nasdaq, to request hearing
XTL Biopharmaceuticals (XTLB) announced that it has received a letter from Nasdaq, dated February 25, notifying the company of the staff’s belief, based upon its review of the company and
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) fro...
XTL Biopharmaceuticals Aims to Acquire Stake in NeuroNOS from Beyond Air (XAIR)
XTL Biopharmaceuticals Aims to Acquire Stake in NeuroNOS from Beyond Air (XAIR)
XTL Biopharmaceuticals provides update on recent developments
XTL Biopharmaceuticals (XTLB) announced that it is working to close the acquisition of 85% of the shares of NeuroNOS from Beyond Air (XAIR) following the execution of the binding letter
XTL Update on Recent Developments
RAMAT GAN, ISRAEL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced that it is working diligently to close the acquisition...
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
RAMAT GAN, ISRAEL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from ...
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease...
XTL Biopharmaceuticals To Acquire 85% Stake In NeuroNOS Ltd For $32.5 Mln
(RTTNews) - XTL Biopharmaceuticals Ltd. (XTLB), a biopharmaceutical company, Tuesday announced that it has agreed to acquire 85 percent of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. (XAIR), a bio...
Beyond Air (XAIR) Moves NeuroNOS to XTL Biopharmaceuticals Through Acquisition Deal
Beyond Air (XAIR) Moves NeuroNOS to XTL Biopharmaceuticals Through Acquisition Deal
XTL Biopharmaceuticals to acquire 85% of Beyond Air’s NeuroNOS for $32.5M
XTL Biopharmaceuticals (XTLB) announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air (XAIR), a biotechnology company pioneering disease-modifying therapeutics target...
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from ...